PROLIGHT DIAGNOSTICS AB |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.15 SEK | +4.17% |
|
+23.97% | -50.17% |
| May. 17 | Prolight Diagnostics Gets SEK17 Million Grant to Advance Product Development | MT |
| May. 17 | Prolight Diagnostics AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Sales 2022 | 35.27M 3.39M | Sales 2023 | 24.22M 2.33M | Capitalization | 150M 14.38M |
|---|---|---|---|---|---|
| Net income 2022 | -12M -1.15M | Net income 2023 | -135M -12.97M | EV / Sales 2022 | 0.02 x |
| Net cash position 2022 | 54.11M 5.2M | Net cash position 2023 | 13.27M 1.28M | EV / Sales 2023 | 5.63 x |
| P/E ratio 2022 * |
-
| P/E ratio 2023 |
-0.63
x | Employees | 16 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 29.54% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +4.17% | ||
| 1 week | +23.97% | ||
| Current month | +3.45% | ||
| 1 month | -3.85% | ||
| 3 months | -15.25% | ||
| 6 months | -55.62% | ||
| Current year | -50.17% |
1 week
0.14
0.15
1 month
0.120.15
Current year
0.120.29
1 year
0.121.70
3 years
0.121.83
5 years
0.124.30
10 years
0.128.06
| Managers | Title | Age | Since |
|---|---|---|---|
Masoud Khayyami
FOU | Founder | 61 | 98-12-31 |
Ulf Bladin
CEO | Chief Executive Officer | 60 | 20-06-30 |
Henrik Ljung
DFI | Director of Finance/CFO | 66 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 71 | 05-12-31 | |
Maria Holmlund
BRD | Director/Board Member | 68 | - |
Masoud Khayyami
FOU | Founder | 61 | 98-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-05 | 0.15 | +4.17% | 648,428 |
| 24-06-04 | 0.144 | +1.41% | 1,060,315 |
| 24-06-03 | 0.142 | -2.07% | 1,600,398 |
| 24-05-31 | 0.145 | +23.93% | 1,262,034 |
| 24-05-30 | 0.117 | -3.31% | 1,466,984 |
End-of-day quote NORDIC GROWTH MARKET, June 04, 2024
More quotes
Prolight Diagnostics AB (publ) is a Sweden-based medical technology company. Together with Technology Partners, the Company develops patient-close test systems based on patented technology, for use in so-called Point of Care Testing (POCT). POCT tests are performed outside the traditional hospital laboratory, small mobile instruments enable testing near the patient and provide quick test answers. The Company focuses on the heart marker troponin.
Calendar
2024-08-27
- Q2 2024 Earnings Release
| 1st Jan change | Capi. | |
|---|---|---|
| -50.17% | 7.19M | |
| -39.50% | 8.41B | |
| +10.24% | 3.82B | |
| -0.25% | 2.33B | |
| -21.06% | 2.02B | |
| -21.37% | 1.67B | |
| +29.77% | 1.14B | |
| +27.83% | 760M | |
| -9.39% | 697M | |
| -21.43% | 566M |
- Stock Market
- Equities
- PRLD Stock
